Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Bullboard Posts
Post by TheRock07on Jul 18, 2016 8:17pm
182 Views
Post# 25063572

Sound Familiar ?

Sound Familiar ?If it does, then it's how Paladin was built by the Goodmans and sold for total consideration of $3 billion.

Paladin was formed in 1995, with just a single drug and a market cap of $1 million.
4 years later and sales had advanced to $10 million and the market cap to $85 million.

Acquire and merge was goodie's favourite move .....PDP and ?

 

From an earlier research report.. 

Paladin Labs (PLB) is a specialty pharmaceutical company focused
on acquiring, in-licensing, marketing and distributing pharmaceutical products primarily for Canadian markets.

Its core focus is on smaller, niche markets and products which are unlikely to compete with larger pharmaceutical companies (pharmas). These markets include specialty
therapeutic elds and other geographic markets (excluding the US and Europe).
In the Canadian pharmaceutical space, PLB has carved a niche
market for itself with its focus on specialty therapeutic elds and the development of synergistic relations with other pharmas.

PLB cultivates long-term relationships with the larger pharmas by sourcing and distrib- uting under-promoted or mature drugs produced by the large pharmas
whose revenue potential are not signi cant enough.

To smaller pharmas, where marketing can incur excessive expense and requires expertise, Paladin positions itself as a marketing and distributing partner in ex


Bullboard Posts